Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study
Author(s): ,
Vincent Mallet
Affiliations:
Institut Pasteur, Inserm, Unité 1223, Paris, France
Corresponding author. Address: Département d’Hépatologie, AP-HP, Hôpital Cochin; Université Paris Descartes, Paris, France, Inserm UMS20, Institut Pasteur; Paris, France; Tel.: +33 (0) 1 58 41 30 12.
,
Stanislas Pol
Affiliations:
Institut Pasteur, Inserm, Unité 1223, Paris, France
,
Philippe Sogni
Affiliations:
Institut Pasteur, Inserm, Unité 1223, Paris, France
,
Alain Hernvann
Affiliations:
Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Cochin, Biology Service, Paris, France
,
Rui Batista
Affiliations:
Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Cochin, Pharmacy Service, Paris, France
,
Anais Vallet-Pichard
Affiliations:
Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Cochin, Hepatology Service, France
Lucia Parlati
Affiliations:
Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Cochin, Hepatology Service, France
EASL LiverTree™. Mallet V. Dec 1, 2018; 256781
Prof. Vincent Mallet
Prof. Vincent Mallet
Contributions
Journal Abstract
References
This article does not have an abstract to display.Keyword(s)
Immune checkpoint inhibitor, Drug-induced liver injury, Observational study
[1]. E. De Martin - Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
[2]. N.P. Chalasani - ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
[3]. A.M. Eggermont - Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy
[4]. J.S. Weber - Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma
[5]. A.M.M. Eggermont - Adjuvant pembrolizumab versus placebo in resected stage III melanoma
[6]. L. Gandhi - Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
[7]. A.B. El-Khoueiry - Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies